E-LIB Suche - Ergebnisse für: Offner, F.

1

Peritoneal papillary mesothelioma in situ: BAP1 mutation wi..:

Vitlarov, Nikola ; Burtscher, E. ; Pfeiffenberger, E....
Virchows Archiv. 483 (2023) 6 - p. 873-878 , 2023

Link: https://doi.org/10.1007/..

2

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R..:

Falchi, L. ; Clausen, M. R. ; Offner, F....
Hematological Oncology. 41 (2023) S2 - p. 207-208 , 2023

Link: https://doi.org/10.1002/..

3

GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS ..:

Carlo‐Stella, C. ; Hutchings, M. ; Offner, F....
Hematological Oncology. 41 (2023) S2 - p. 63-65 , 2023

Link: https://doi.org/10.1002/..

4

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE A..:

Hutchings, M. ; Dickinson, M. ; Carlo‐Stella, C....
Hematological Oncology. 41 (2023) S2 - p. 136-138 , 2023

Link: https://doi.org/10.1002/..

5

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORI..:

Cordoba, R. ; Falchi, L. ; Phillips, T....
HemaSphere. 6 (2022) - p. 1101-1102 , 2022

Link: https://doi.org/10.1097/..

6

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HA..:

Dickinson, M. ; Carlo-Stella, C. ; Morschhauser, F....
HemaSphere. 6 (2022) - p. 121-122 , 2022

Link: https://doi.org/10.1097/..

7

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANT..:

Hasselbalch Riley, C. ; Hutchings, M. ; Yoon, S.-S....
HemaSphere. 6 (2022) - p. 81-82 , 2022

Link: https://doi.org/10.1097/..

8

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TRE..:

Clausen, M. R. ; Offner, F. ; Belada, D....
HemaSphere. 6 (2022) - p. 1100-1101 , 2022

Link: https://doi.org/10.1097/..

9

S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM TH..:

Dekhtiarenko, I. ; Lelios, I. ; Attig, J....
HemaSphere. 6 (2022) - p. 74-75 , 2022

Link: https://doi.org/10.1097/..

10

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STU..:

Dimopoulos, M.-A. ; Amaador, K. ; Minnema, M. C....
HemaSphere. 6 (2022) - p. 995-996 , 2022

Link: https://doi.org/10.1097/..

11

REAL WORLD APPLICATION OF R‐CHOP FOR DIFFUSE LARGE B‐CELL L..:

Daneels, W ; Rosskamp, M ; Macq, G...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRON..:

Coutre, S. E. ; Barr, P. M. ; Owen, C....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTI..:

Janssens, A ; Snauwaert, S ; Bron, D...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLEC..:

Fowler, N. H. ; Dickinson, M. ; Martinez‐Lopez, J....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

PCN325 Health Utility in Relapsed/Refractory Diffuse Large ..:

Casasnovas, R.O. ; Daniele, P. ; Tremblay, G....
Value in Health. 23 (2020) - p. S479-S480 , 2020

Link: https://doi.org/10.1016/..